JAMA:迄今最大规模长期研究证实,IL-6受体拮抗剂提高重症COVID-19患者6个月生存率的概率...
鉴于此,近期澳大利亚莫纳什大学Alisa M. Higgins教授领导的研究团队在《美国医学会杂志》(JAMA)发表了题为:Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial 的重要研究成果,给重症COVID-19患者的临床治疗方案提供了重要证据。
180天死亡率的Kaplan-Meier曲线
该研究领导者Lisa Higgins 博士表示,治疗COVID-19重症患者已有近三年时间,但在了解COVID-19重症患者的长期生存、与健康相关的生活质量和残疾方面,确仍处于早期阶段。这项研究发现对COVID-19以及更普遍的重症监护具有重要的临床和研究意义,因为它们提供了证据,表明短期的院内治疗效果可以持续较长时间。
1.Writing Committee for the REMAP-CAP Investigators, Higgins AM, Berry LR, et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2022. doi:10.1001/jama.2022.23257.
2.Haimei MA. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications[J] Clin Appl Thromb Hemost. 2020;26:1076029620944497. doi: 10.1177/1076029620944497.
3.Zanza C, Racca F, Longhitano Y, et al. Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection[J] Int J Environ Res Public Health. 2021;18(3):1268. doi: 10.3390/ijerph18031268.
4.梅 恒, 胡 豫. 新型冠状病毒肺炎 (COVID-19) 患者出凝血功能障碍病因分析及诊治策略[J] 中华血液学杂志 2020;41(3):185–191. doi: 10.3760/cma.j.issn.0253-2727.2020.0002.
5.中华医学会呼吸病学分会, 中国医师协会呼吸医师分会 中国成人2019冠状病毒病的诊治与防控指南[J] 中华医学杂志 2021;101(18):1293–1356.
6.Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6[J] Cancer Immunol Res. 2014;2(4):288–294. doi: 10.1158/2326-6066.CIR-14-0022. 28. Zhang J, Hao Y, Ou W, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study[J] J Transl Med. 2020;18(1):406. doi: 10.1186/s12967-020-02571-x.
7.29. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, Creactive protein, and procalcitonin in patients with COVID-19[J] J Clin Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370.
8.Zhang J, Gao XL, Yang LH. [Research progress in coagulation dysfunction and its relationship with cytokine storm syndrome in patients with severe/critical COVID-19]. Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):700-704. Chinese. doi: 10.3760/cma.j.issn.0253-2727.2021.08.019.
白度搜_经验知识百科全书 » JAMA:迄今最大规模长期研究证实,IL-6受体拮抗剂提高重症COVID-19患者6个月生存率的概率...
0条评论